Maternal and Fetal Outcomes Following Percutaneous Transluminal Mitral Commissurotomy in Pregnant Women with Critical Mitral Stenosis: An Experience of a Tertiary Care Center from Northern India

ABSTRACT
Background: Rheumatic mitral stenosis is the common valvular heart disease seen during pregnancy. Percutaneous transvenous mitral commissurotomy is an effective, safe, and recommended treatment for critical mitral stenosis during pregnancy. We hereby report the maternal and fetal outcomes of pregnant women subjected to percutaneous transvenous mitral commissurotomy at our institute.

Methods: Seventy consecutive pregnant women with critical mitral stenosis, who underwent PTMC during the last 10 years, were retrospectively analyzed. All patients had a detailed clinical and obstetric evaluation and were optimally managed with drugs, before the intervention. A comprehensive pre- and post-percutaneous transvenous mitral commissurotomy transthoracic echocardiographic evaluation was performed. Detailed obstetric and fetal outcomes were noted at the time of delivery. Six weeks of post-partum follow-up was noted in all patients.

Results: The mean gestational age at the time of percutaneous transvenous mitral commissurotomy was $29.5 \pm 6.68$ weeks. Percutaneous transvenous mitral commissurotomy was successful in 97% of patients. Post-percutaneous transvenous mitral commissurotomy New York Heart Association functional class, mitral valve area, trans-mitral pressure gradient, and left atrial pressure had a significant improvement ($P < .001$). The mean gestational age at the time of delivery was $36.92 \pm 3.02$ weeks. The mean birth weight of live newborn was $2.29 \pm 0.55$ kg. The fetal complications include growth restriction in 62.85%, preterm delivery in 34.37%, and low birth weight in 67.21%. A delayed percutaneous transvenous mitral commissurotomy at about 30 weeks of gestation did not affect the maternal and fetal outcomes.

Conclusion: Percutaneous transvenous mitral commissurotomy is safe and efficacious in managing pregnant women with critical mitral stenosis. There was a significant improvement in clinical symptoms and echocardiographic parameters following percutaneous transvenous mitral commissurotomy.

Keywords: Balloon mitral valvuloplasty, mitral stenosis, Percutaneous transvenous mitral commissurotomy, pregnancy, valvular heart disease

INTRODUCTION
Chronic rheumatic heart disease (RHD) is the most common valvular heart disease during pregnancy in developing countries like India. The mitral valve is the commonly affected valve in RHD. Though both mitral stenosis (MS) and mitral regurgitation (MR) can clinically manifest for the first time during pregnancy, it is MS that is more symptomatic due to pregnancy-related hemodynamic changes. Pregnancy increases blood volume, cardiac output, and heart rate and decreases peripheral vascular resistance. These changes exaggerate the stenotic physiology, cardiac decompensation, and pulmonary edema. Critical MS is associated with increased maternal and fetal morbidity and mortality. According to the modified World Health Organization classification, critical MS with pulmonary artery hypertension and New York Heart Association (NYHA) functional class II is
associated with high maternal morbidity and mortality, having a cardiac event rate from 40% to 100%. Medical treatment which includes β-blockers and diuretics can control the symptoms in mild-to-moderate cases; however, those with critical MS with decompensation and pulmonary edema need mechanical dilatation of the mitral valve. Surgical mitral commissurotomy is associated with significant maternal and fetal mortality. Percutaneous transvenous mitral commissurotomy (PTMC) is an effective, safe, and recommended treatment for critical MS during pregnancy. We hereby report our experience of 70 consecutive pregnant women with critical MS, who underwent PTMC at our institute during the last 10 years.

**METHODOLOGY**

We had 99 pregnant women with critical MS, out of a total of 398 RHD patients seen in the cardio-obstetric clinic during the last 10 years, from the year 2009 to 2018. Seventy patients had undergone PTMC and were retrospectively analyzed. Twenty-nine patients with critical MS did not have PTMC because of the reasons such as delayed presentation with active labor (n = 15), left atrial or left atrial appendage clot (n = 9), and refusal for the intervention (n = 5). Patients with MS having mitral valve area (MVA) of <1.2 cm² in NYHA functional class III or IV or a recent worsening of functional class without any precipitating factors were intervened. These patients did not have any previous medical consultation for underlying RHD, hence were not intervened before the current pregnancy. Patients with associated moderate-to-severe MR and significant aortic valve disease were excluded from the study. All patients had a detailed clinical and obstetric evaluation and were optimally managed with drugs, before the intervention. They had a comprehensive transthoracic 2-dimensional echocardiography before PTMC to assess the mitral valve morphology, commissural calcification, severity of subvalvular pathology, and severity of MS. The MVA was calculated by 2-dimensional echocardiography in the para-sternal short-axis view. The trans-mitral gradient was assessed using a continuous-wave Doppler technique. None of the patients had trans-esophageal echocardiography. All patients received an injection of 17-alpha-hydroxyprogesterone caproate 250 mg intra-muscularly, before PTMC to prevent preterm labor. Percutaneous transvenous mitral commissurotomy was performed using an Inoue balloon and a standard trans-septal antegrade approach. Right-side heart catheterization was not performed to avoid excess radiation in pregnant women. A lead apron was wrapped circumferentially around the abdomen of the patient to avoid fetal irradiation. Repeat echocardiography was performed within 24 h of PTMC to assess MVA, trans-mitral gradient, and severity of MR. PTMC was considered successful when MVA had >50% increase or ≥ 1.5 cm², and without severe MR. The functional class of patients was also assessed following the intervention and during follow-up. All women had obstetric evaluation on the same day after PTMC and were followed regularly at the cardio–obstetric clinic. Any maternal or fetal complications of pregnancy were noted. Informed consent was obtained from all the study participants. The study was approved by the Institute Ethics Committee for retrospective analysis of the database, vide no. SPL-1304, dated November 24, 2020. The study conforms to the ethical guidelines of the Declaration of Helsinki.

**Table 1. Baseline Characteristics of Pregnant Women Who Underwent Percutaneous Transluminal Mitral Commissurotomy (PTMC) (n = 70)**

| Value                          | Median (Range) |
|-------------------------------|----------------|
| Age (years)                   | 25.71 ± 3.6*   |
| Period of Gestation at the time of PTMC (weeks) | 29.5 ± 6.68*   |
| Primigravida [number (%)]     | 46 (65.71%)    |
| Mitral regurgitation [number (%)] Absent | 52 (74.29%)    |
| Mild                          | 18 (25.71%)    |
| 2-Dimensional mitral valve area (cm²) | 0.73 ± 0.12*   |
| Atrial fibrillation [number (%)] | 4 (5.71%)    |
| Wilkins echocardiographic score (number) | 6.64 ± 0.93*   |

Data given as Mean ± 1SD*.

HIGHLIGHTS

- Percutaneous transvenous mitral commissurotomy (PTMC) is an effective, safe, and recommended treatment for rheumatic mitral stenosis (MS) during pregnancy.
- Seventy consecutive pregnant women of critical MS, who underwent PTMC during the last 10-years were retrospectively analysed.
- The mean gestational age at the time of PTMC was 29.5 ± 6.68 weeks.
- PTMC was successful in 97% of patients. Post PTMC NYHA functional class, mitral valve area, trans-mitral pressure gradient, and left atrial pressure had significant improvement (P < .001).
- The mean gestational age at the time of delivery was 36.92 ± 3.02 weeks.

Statistical Analysis

Descriptive statistics are used to summarize the data. Continuous variables are presented as mean ± standard deviation (normally distributed data) or median (inter-quartile range [IQR], skewed data). Categorical variables are expressed in percentages. The normality of the data was analyzed by Kolmogorov–Smirnov test. Inferential
A Marginal Homogeneity test (Stuart–Maxwell test) was used to assess the improvement in NYHA functional class following the intervention. A paired \( t \)-test was used to analyze the pre- and post-procedure improvement in MVA and trans-mitral gradient. All statistical analyses were performed with IBM SPSS software version 23.

### RESULTS

Seventy consecutive pregnant females of age 25.71 ± 3.6 years were enrolled in the study. Baseline characteristics were shown in Table 1. The mean gestational age at the time of PTMC was 29.5 ± 6.68 weeks (range: 16-38 weeks).

| Parameters | Pre-PTMC | Post-PTMC | \( P \) |
|------------|----------|-----------|-------|
| Mitral valve area (cm\(^2\)) | 0.73 ± 0.12 | 1.61 ± 0.20 | <.001* |
| Peak trans-mitral gradient (mm Hg) on echocardiography | 30.96 ± 8.40 | 13.66 ± 3.60 | <.001* |
| Mean trans-mitral gradient (mm Hg) on echocardiography | 19.11 ± 5.84 | 5.67 ± 2.28 | <.001* |
| Mean trans-mitral gradient (mm Hg) on catheterization | 18.14 ± 6.38 | 1.71 ± 2.16 | <.001* |
| Mean left atrial pressure (mm Hg) on catheterization | 28.34 ± 7.60 | 13.60 ± 5.93 | <.001* |
| NYHA class [number (%)] | I-0 (0%) | I-54 (77.14%) | <.001* |
| II-4 (5.71%) | II-14 (20.00%) |
| III-38 (54.28%) | III-1 (1.42%) |
| IV-28 (40.00%) | IV-1 (1.42%) |

*Paired \( t \)-test and *marginal homogeneity test were used for statistical analysis.

Twenty-eight (40%) patients were in NYHA class IV, 38 (54.28%) were in class III, and 4 (5.72%) were in NYHA class II, before PTMC (Table 2). Four patients presented with significant haemoptysis at the time of the presentation. Four patients were in atrial fibrillation, while the rest were in normal sinus rhythm. Eighteen patients had associated mild MR, while the rest did not have any MR. The median Wilkins echocardiographic score of the mitral valve was 6 (range: 6-9). There was significant improvement in MVA (0.73 ± 0.12 cm\(^2\) to 1.61 ± 0.20 cm\(^2\), \( P \leq .001 \)) and trans-mitral gradient (19.11 ± 5.84 to 5.67 ± 2.28 mm Hg, \( P < .001 \)), following PTMC (Table 2). Mean fluoroscopy time for PTMC was 4.44 ± 3.33 minutes (range: 1.18-20.10 minutes). Percutaneous transvenous mitral commissurotomy...
was successful in 68 out of 70 patients (97.14%) and showed a significant transition from higher to lower NYHA class (Marginal Homogeneity statistic—7965, P < .001) (Figure 1). Among the 2 unsuccessful patients, 1 patient had severe MR, while the other had a failed procedure as Inoue balloon could not cross the mitral valve despite repeated attempts. Both the patients were managed with optimal medical treatment and had uneventful delivery without any further intervention, during peri-partum period. The patient with severe MR had spontaneous labor at 38 weeks and delivered a healthy baby of 2.8 kg weight. Another patient of failed PTMC delivered a 1.7 kg baby at 34 weeks of gestation. Six (8.57%) patients developed moderate MR. One patient had an inadvertent puncture of ascending aorta during trans-septal puncture. She remained hemodynamically stable, without any pericardial effusion, and had cesarean-assisted delivery of a healthy child a week later. Two patients developed hemodynamically unstable supra-ventricular tachycardia during PTMC, one responded with adenosine, while the other required direct-current cardioversion after failed adenosine injection. One patient presented with acute pulmonary edema, cardiogenic shock, and severe metabolic acidosis at 30 weeks of gestation. Though she had a successful emergency PTMC but died of cardiac arrest after an hour of intervention. Another patient had transient right upper limb and facial paresis following PTMC, which was completely resolved within 24 hours of heparin infusion. None of the patients developed any local vascular complication, cardiac perforation, or tamponade.

**Obstetric Outcomes**

Forty-six (65.71%) patients were primigravida. There were 2 maternal deaths, 1 patient with cardiogenic shock and severe metabolic acidosis died following PTMC, while another patient died of puerperal sepsis following a cesarean section at 37 weeks of gestation. Obstetric data were available for 64 patients (Table 3), as 5 patients had delivered at a nearby local hospital, while 1 patient died following PTMC. Those 5 patients had uneventful delivery and had favorable maternal and neonatal outcomes at local hospitals, as per telephonic conversation. Common obstetric complications were intrauterine growth restriction (<10 percentile for gestational age) in 44 (62.85%) patients and prematurity (<37 weeks of gestational age at the time of delivery) in 22 (34.37%) patients (Table 3). Other complications included anemia, gestational hypertension, stillbirth, second-trimester abortion, and severe preeclampsia/eclampsia (Table 3). The average period of gestation at the time of delivery was 36.92 ± 3.02 weeks. Fifty-one patients had a normal vaginal delivery, 12 had a cesarean section, while 1 had a second-trimester abortion for intra-uterine death of the fetus.

**Newborn Outcomes**

The average weight of 61 live newborns was 2.29 ± 0.55 kg. Low birth weight (<2.5 kg) was seen in 41 out of 61 live birth (67.21%). There were three intra-uterine deaths, one in the second trimester and two in the third trimester (Table 3). All 61 newborns had an Apgar score of more than 7 at 5 minutes

### Table 3. Obstetric and Fetal Outcomes in the Cohort

| Period of Gestation at Delivery (Weeks) | Maternal complications during pregnancy (n = 70) [number (%)] | Fetal complications (n = 70) [number (%)] | Mode of delivery (n = 64) [number (%)] | Preterm (n = 64) [number (%)] | Live newborn birth weight (kg) (n = 61) | Low birth weight ≤2.5 kg [number (%)] |
|----------------------------------------|---------------------------------------------------------------|------------------------------------------|---------------------------------------|---------------------------------|--------------------------------------|-------------------------------------|
| 36.92 ± 3.02 (Mean ± 1SD) 37.5 (Median), (Range 30-32) | Anemia-13 (18.57%) Gestational hypertension-3 (4.28%) Eclampsia/preeclampsia-2 (2.85%) Post PTMC severe MR-1 (1.42%) Transient ischemic attack/paralysis-1 (1.42%) Maternal Death-2 (2.85%) | Abortion: 1 (1.42%) Still birth: 3 (4.28 %) Growth restriction (IUGR): 44 (62.85%) | Vaginal delivery: 51 (79.68%) Cesarean section: 12 (18.75%) Abortion: 1 (1.56%) | 22 (34.37%) | 2.29 ± 0.55 (mean ± 1SD) 2.34 (median), (range 0.8-2.95) | 41 out of 61 live birth (67.21%) |

**Table 4. Relationship of Obstetric Outcomes with Timing of Percutaneous Transluminal Mitral Commissurotomy (PTMC)**

| Period of gestation at delivery (weeks) | PTMC ≤24 weeks (n = 23) | PTMC >24 weeks (n = 47) | P |
|----------------------------------------|--------------------------|--------------------------|---|
| 36.80 ± 3.29 (mean ± 1SD) 37 (median) (range 31-41) | 36.83 ± 5.99 (mean ± 1SD) 37.28 (median) (range 29-42) | .980 |

**Fetal Complications (n = 70)**

| Abortion (n = 1) | Still birth (n = 3) | Growth restriction (IUGR) (n = 44) | 13 | 31 | .440 |
|-----------------|-------------------|-------------------------------|----|----|------|

**Newborn Outcomes**

| Preterm (n = 22) | Birth weight (kg) (n = 61) | Low birth weight (n = 41) |
|-----------------|----------------------------|---------------------------|
| 10 | 2.22 ± 0.75 (mean ± 1SD) 2.3 (median), (range 1.33-3.25) (n = 19) | 12 |
| 12 | 2.26 ± 0.54 (mean ± 1SD) 2.3 (median), (range 0.8-3.16) (n = 42) | 29 |

IUGR, intrauterine growth retardation; MR, mitral regurgitation; PTMC, percutaneous transluminal mitral commissurotomy.
Table 5. Published Case Series of Percutaneous Transluminal Mitral Commissurotomy (PTMC) in Pregnant Women and Their Comparison with the Index Study

| Authors            | No of Patients | Maternal Age in Years | Gestational Age in Weeks at the Time of PTMC | Gestational Age in Weeks at Delivery | Mitral Valve Area in cm² | Mean Pressure Gradient in mm Hg | Mitral Valve Area in cm² | Mean Pressure Gradient in mm Hg | Technical Success in % | Fluoroscopy Time in Minutes |
|--------------------|----------------|-----------------------|---------------------------------------------|-------------------------------------|--------------------------|-------------------------------|--------------------------|-------------------------------|--------------------------|-------------------------------|
| Abdi²⁰             | 33             | 31.55 ± 6.3           | 21.85 ± 5.8                                 | –                                   | 0.83 ± 0.13               | 15.5 ± 7.4                   | 1.38 ± 0.29               | 2.3 ± 2.3                     | 97                       | –                             |
| de Souza²¹         | 21             | 24.6 ± 4.8            | 25.2 ± 7.2                                  | –                                   | 0.96 ± 0.15               | 15.9 ± 8.6                   | 1.84 ± 0.30               | 4.7 ± 3.3                     | 95                       | –                             |
| Esteves²¹¹         | 71             | 27 ± 6                | 24 ± 7                                      | 38.0 ± 1.2                          | 0.9 ± 0.2                 | 18 ± 7                       | 2.0 ± 0.3                 | 3.9 ± 3.1                     | 94                       | –                             |
| Ben Farhat²¹²      | 44             | 29 ± 6                | 26 ± 6                                      | –                                   | 1.07 ± 0.21               | 22 ± 8                       | 2.32 ± 0.36               | 5 ± 3                         | 90.9                     | 16 ± 7                        |
| Kalra²¹³           | 27             | 24.9 ± 3.14           | 22.2 ± 4.3                                  | –                                   | 0.78 ± 0.19               | 30.5 ± 7.6                   | 2.2 ± 0.12                | 6.1 ± 2.6                     | 96.3                     | 5.6 ± 2.2                     |
| Vinayakumar²¹⁴     | 49             | 25.7 ± 3.1            | 23.5 ± 5.2                                  | –                                   | 0.93 ± 0.17               | –                            | 1.75 ± 0.27               | –                             | 95.9                     | 6.4 ± 1.2                     |
| Gupta²¹           | 40             | 24 ± 6.5              | 21 ± 11                                     | –                                   | 0.8 ± 0.2                 | 26 ± 7                       | 1.7 ± 0.2                 | 9 ± 5                         | 97.5                     | 7.8 ± 1.9                     |
| Salehi R.²⁶        | 24             | 29.45 ± 5.05          | 83% in second trimester                     | –                                   | 0.92 ± 0.15               | 11.03 ± 3.61                 | 1.57 ± 0.16               | 5 ± 1.3                      | 100                     | –                             |
| Joshi²⁷            | 30             | 24.80 ± 4.34          | 25.3 ± 3.93                                | –                                   | 0.85 ± 0.16               | –                            | 1.60 ± 0.27               | –                             | 100                     | 3.97                          |
| Ananthakrishna Pillai²⁸ | 96         | 26.7 ± 7.2            | 23.4 ± 10.9                                 | –                                   | 0.98 ± 0.12               | 26.7 ± 1.3                   | 1.32 ± 0.06               | 9.6 ± 11.2                    | 82.2                     | –                             |
| Rathakrisnan²⁹     | 38             | 25 ± 6                | 90% in second trimester                     | –                                   | 0.8 ± 0.3                 | 16 ± 4                      | 1.7 ± 0.4                 | 4 ± 3                         | 95                      | –                             |
| Routray²⁰          | 40             | 23.4 ± 4.8            | 24.2 ± 4.6                                  | –                                   | 0.82 ± 0.34               | 27.8 ± 9.6                   | 1.9 ± 0.4                 | 6.8 ± 4.2                     | 100                     | 5.5 ± 3.8                     |
| Mishra S²¹         | 85             | 22.7 ± 4.1            | 24.8 ± 4.7                                  | –                                   | 0.75 ± 0.5                | 291 ± 9.1                    | 2.0 ± 0.5                 | 7.2 ± 4.1                     | 94                      | 3.6 ± 3.2                     |
| Nercolini²²        | 44             | 28 ± 6                | 23 ± 6                                      | –                                   | 1.17 ± 0.26               | 16.22 ± 5.55                 | 2.06 ± 41                 | 7.94 ± 3.75                    | 95                      | –                             |
| Sharma²³           | 10             | 25.7 ± 3.5            | 18.4                                        | 39.2                                | 0.8 ± 0.2                 | –                            | 1.75 ± 0.27               | –                             | 100                     | –                             |
| Present Study      | 70             | 25.71 ± 3.6           | 29.5 ± 6.6                                  | 36.92 ± 3.0                         | 0.73 ± 0.12               | 1911 ± 5.84                  | 1.61 ± 0.20               | 5.67 ± 2.28                    | 9714                    | 4.44 ± 3.33                   |
and none required any special care following delivery and during 6 weeks of follow-up.

Sub-Group Analysis
We had a sub-group analysis of maternal and fetal outcomes in patients for early (≤24 weeks of gestation) versus late (>24 weeks of gestation) PTMC during pregnancy. There was no significant difference in the period of gestation at the time of delivery and birth weight of the newborn between the two groups. Intrauterine growth restriction and low birth weight were also equally distributed in the two groups (Table 4).

DISCUSSION

Chronic RHD is primarily restricted to developing countries and some poor, indigenous populations of developed countries. Due to high prevalence and lack of screening during childhood, chronic RHD is frequently diagnosed during adulthood when there is a progression of the disease or an increase in hemodynamic stress. Pregnancy-associated hemodynamic stress decompensates these asymptomatic patients, especially those with critical MS. Though the medical treatment which includes β-blockers and diuretics can initially improve the symptoms, in the late course of pregnancy, the clinical deterioration would require mechanical dilatation of stenotic mitral valve.1,4,5 Table 5 describes the demographic and PTMC details of various published series of pregnant patients.7-20 The mean age of pregnant women in the present study was similar to the other studies. The mean gestational age at the time of PTMC was 29.5 ± 6.68 weeks, which was higher compared to previously published studies having a range of 21-25 weeks (Table 5). The possible reason for the late PTMC at our institute was delayed referrals from peripheral centers. Two of the largest case series by Ananthakrishna Pillai et al18 (n = 96) and Mishra et al19 (n = 85) demonstrated a technical success rate of PTMC in 82% and 94% patients, respectively, while we had a success rate of 97%. There was a significant improvement of MVA and trans-mitral gradient following PTMC, as reported by other authors.7-23 Post-PTMC severe MR had been reported in 1.1-6.5% of pregnant women.6,10-14,18-20,21 We had one patient (1.4%) with severe MR, who was medically managed and had an uneventful delivery. Similar to our experience of transient ischemic attack (n = 1), three other authors had also reported one patient each in their series of PTMC.11,22-23 Cardiac tamponade14,21 and vascular access site complications15,23,29 as reported by others were not experienced by us. Certain patients with poor pre-procedural hemodynamics such as intractable pulmonary edema, cardiogenic shock, post-cardiopulmonary resuscitation, and disseminated intravascular coagulation had high mortality despite successful PTMC,19 as observed in one of our patients. The reported mean fluoroscopy time for PTMC ranged from 3.6 to 16.0 minutes,12-15,20-21 which was 4.44 ± 3.33 minutes in the index study. The gestational age at the time of delivery in the present study (36.92 ± 3.02 weeks) was lower compared to other studies.12,21 We observed cesarean section in 18.75% and stillbirth in 4.28%, which was comparable with our earlier published data of a similar trend in pregnant women with chronic RHD.3,24 Two of the South Asian series had reported 14%15 and 17%14 rate of cesarean section in post-PTMC patients. The average birth weight of the newborn in the present study (i.e., 2.29 ± 0.55 kg) was lower compared to the reported birth weight by 4 case series from the South Asian region (2.32-2.64 kg).15-17,21 Certain Western series had reported even higher birth weight ranging from 2.8 kg to 3.2 kg in post-PTMC patients.11,12,20 The reasons for low birth weight in this geographical region are multifactorial including delayed referral, poor socioeconomic status, NYHA classes III and IV, anemia, severe valvular heart disease, and gestational hypertensive.1,5,24 We had reported a lower mean birth weight of 2.4-2.5 kg in pregnant women suffering from chronic RHD.3,24 A higher rate of intrauterine growth restriction and preterm labor as observed by us is also reported by other authors1,5 and by our team.3,24 The limitation of the present study includes a retrospective analysis and lack of long-term follow-up of mother and child following the intervention.

CONCLUSION

We demonstrated the safety and efficacy of PTMC in managing pregnant women with critical MS. There was a significant improvement in functional status and echocardiographic parameters following PTMC. A delayed PTMC at about 30 weeks of gestation did not affect the fetal and maternal outcomes in limited number of patients.

REFERENCES

1. van Hagen IM, Thorne SA, Taha N, et al. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease. Circulation. 2018;137(8):806-816. [CrossRef]
2. Ducas RA, Javier DA, D’Souza R, Silversides CK, Tsang W. Pregnancy and percutaneous valvuloplasty in women with severe mitral disease: a systematic review and meta-analysis. *Heart*. 2020;106(7):512-519. [CrossRef]

3. Sawhney H, Aggarwal N, Suri V, Vasishtha K, Sharma Y, Grover A. Maternal and perinatal outcome in rheumatic heart disease. *Int J Gynaecol Obstet*. 2003;80(1):9-14. [CrossRef]

4. Mehta LS, Warnes CA, Bradley E, et al. American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Cardiovascular Considerations in caring for pregnant patients: a scientific statement from the American Heart Association. *Circulation*. 2020;141:e884-e903.

5. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3155-3241. [CrossRef]

6. Pavankumar P, Venugopal P, Kaul U, et al. Closed mitral valvotomy during pregnancy. A 20-year experience. *Scand J Thorac Cardiovasc Surg*. 1988;22(1):11-15. [CrossRef]

7. de Souza JA, Martinez EE Jr, Ambrose JA, et al. Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy. *J Am Coll Cardiol*. 1997;77(6):564-567. [CrossRef]

8. Marjion E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. *N Engl J Med*. 2007;357(5):470-476. [CrossRef]

9. Abd S, Salehi N, Ghodsí B, et al. Immediate results of percutaneous mitral commissurotomy in pregnant women with severe mitral stenosis. *Clin Med Insights Cardiol*. 2012;6:35-39. [CrossRef]

10. Estevés CA, Munoz JS, Braga S, et al. Immediate and long-term follow-up of percutaneous balloon mitral valvuloplasty in pregnant women with rheumatic mitral stenosis. *Am J Cardiol*. 2006;98(6):812-816. [CrossRef]

11. Ben Farhat M, Gamra H, Betbout F, et al. Percutaneous balloon mitral commissurotomy during pregnancy. *Heart*. 1997;77(6):564-567. [CrossRef]

12. Kalra GS, Arora R, Khan JA, Nigam M, Khaliullah M. Percutaneous mitral commissurotomy for severe mitral stenosis during pregnancy. *Catheter Cardiovasc Diagn*. 1994;33(1):28-31. [CrossRef]

13. Vinayakumar D, Vinod GV, Madhavan S, Krishnan MN. Maternal and fetal outcomes in pregnant women undergoing balloon mitral valvotomy for rheumatic mitral stenosis. *Indian Heart J*. 2016;68(6):780-782. [CrossRef]

14. Gupta A, Lokhandwala YY, Sotoskar PR, Salvi VS. Balloon mitral valvotomy in pregnancy: maternal and fetal outcomes. *J Am Coll Surg*. 1998;187(4):409-415. [CrossRef]

15. Salehi R, Aslanabadi N, Taghavi S, Pourafkari L, Imani S, Gohr dust M. Percutaneous balloon mitral valvotomy during pregnancy. *Pak J Biol Sci*. 2013;16(4):198-200. [CrossRef]

16. Rathakrisnan SS, Ramasamy R, Kaliappan T, Gopalan R, Palan imuthu R, Anandhan P. Immediate outcome of balloon mitral valvuloplasty with JOMIVA balloon during pregnancy. *J Clin Diagn Res*. 2015;9(12):OC14-OC17. [CrossRef]

17. Sharma JB, Yadav V, Mishra S, et al. Comparative study on maternal and fetal outcome in pregnant women with rheumatic heart disease and severe mitral stenosis undergoing percutaneous balloon mitral valvotomy before or during pregnancy. *Indian Heart J*. 2018;70(5):685-689. [CrossRef]

18. Suri V, Sikka P, Singla R, Aggarwal N, Chopra S, Vijayvergiya R. Factors affecting the outcome of pregnancy with rheumatic heart disease: an experience from low-middle income country. *J Obstet Gynaecol*. 2019;39(8):1087-1092. [CrossRef]